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PKA catalytic subunit mutations in adrenocortical
Cushing’s adenoma impair association with the
regulatory subunit
Davide Calebiro1,2, Annette Hannawacker1, Sandra Lyga1,2, Kerstin Bathon1,2, Ulrike Zabel1, Cristina Ronchi3,
Felix Beuschlein4, Martin Reincke4, Kristina Lorenz1,5, Bruno Allolio6, Caroline Kisker2,
Martin Fassnacht3,6 & Martin J. Lohse1,2,5
We recently identiﬁed a high prevalence of mutations affecting the catalytic (Ca) subunit of
protein kinase A (PKA) in cortisol-secreting adrenocortical adenomas. The two identiﬁed
mutations (Leu206Arg and Leu199_Cys200insTrp) are associated with increased PKA
catalytic activity, but the underlying mechanisms are highly controversial. Here we utilize a
combination of biochemical and optical assays, including ﬂuorescence resonance energy
transfer in living cells, to analyze the consequences of the two mutations with respect to the
formation of the PKA holoenzyme and its regulation by cAMP. Our results indicate that
neither mutant can form a stable PKA complex, due to the location of the mutations at the
interface between the catalytic and the regulatory subunits. We conclude that the
two mutations cause high basal catalytic activity and lack of regulation by cAMP through
interference of complex formation between the regulatory and the catalytic subunits of PKA.
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P
rotein kinase A (PKA) is the primary mediator of cyclic
AMP (cAMP) in eukaryotic cells and probably the best-
studied protein kinase1. It consists of two regulatory (R)
and two catalytic (C) subunits that assemble into a functional
tetramer. In the holoenzyme, access to the active site cleft of the C
subunit is prevented by interaction with an inhibitory sequence in
the R subunit, which is tightly bound and serves as a tethered
pseudosubstrate (RI subunits) or substrate (RII subunits)1. On
binding of cAMP to two separate sites on each R subunit, the C
subunits are released and become capable of phosphorylating Ser/
Thr residues in a large number of target proteins1.
Endocrine cells are under the strict control of hormones and
local messengers that act primarily through G-protein-coupled
receptors. Several of these receptors activate the cAMP/PKA
pathway, leading in most cases to both increased hormone
production and cell replication. Thus, somatic mutations causing
constitutive activation of the cAMP/PKA pathway have been
shown in several instances to be responsible for tumour formation
and excessive hormone production, ultimately leading to endocrine
disorders such as hyperthyroidism2,3 or gigantism/acromegaly4,5.
Moreover, germline-inactivating mutations in the PRKAR1A
gene, coding for the PKA RIa subunit, have been linked to
Carney complex, a rare syndrome characterized by excess of
several hormones—most commonly cortisol excess (Cushing’s
syndrome) due to the presence of multiple pigmented adrenal
adenomas—as well as by cutaneous and neuronal tumours, skin
and cardiac myxomas, and characteristic lesions of the skin and
mucosae6. Similarly, mosaic, activating mutations of the gene
coding for the Gas protein (GNAS1, guanine nucleotide-binding
protein, alpha-stimulating activity polypeptide 1) are responsible
for the McCune–Albright syndrome, which is characterized by
hormonal disorders, including in some cases cortisol excess due
to adrenal hyperplasia5,7,8. Finally, mutations in PRKAR1A as
well as in PDE11A and PDE8B, coding for two phospho-
diesterases that are responsible for cAMP degradation, have also
been associated with adrenal hyperplasia or unilateral cortisol-
producing adenomas9–12. However, these mutations are found
only in a small fraction of adrenal tumours.
Recently, we identiﬁed a high prevalence of somatic mutations
in PRKACA, coding for the Ca subunit of PKA, in a series of
cortisol-secreting adrenal adenomas leading to Cushing’s syn-
drome13. The two identiﬁed mutations (c.617A4C, p.Leu206Arg
and c.595_596insCAC, p.Leu199_Cys200insTrp) were present in
the tumours but not in the surrounding normal adrenal tissue or
in peripheral leucocytes. When expressed in cell lines, Ca
subunits harbouring these mutations displayed normal catalytic
activity, but were constitutively active as shown by the fact that
their activity could no longer be suppressed by an excess of R
subunits and was virtually not regulated by cAMP13. The same
Leu206Arg mutation was very recently reported in similar studies
by other groups14–16. These studies conﬁrmed that this mutation
causes increased PKA activity. However, there is considerable
controversy regarding the underlying biochemical mechanism.
Here we use a combination of biochemical and optical methods
based on ﬂuorescence resonance energy transfer (FRET) to clarify
the mechanism of action of both PRKACA mutations associated
with cortisol-secreting adrenal adenomas. The results indicate
that these mutations interfere with the formation of a stable PKA
holoenzyme both in vitro and in living cells, thus providing a
molecular explanation for the constitutive activation of PKA
caused by both mutations.
Results
In silico analysis of PRKACA mutations. Both PRKACA
mutations identiﬁed in cortisol-secreting adrenal adenomas
(c.617A4C, p.Leu206Arg and c.595_596insCAC, p.Leu199_Cys
200insTrp) affect amino acids in the so-called Pþ 1 loop1 that are
positioned right at the interface between the R and C subunits
(Fig. 1a,b). In particular, Leu206 is part of the active site cleft of
the catalytic subunit and participates in the formation of a
hydrophobic pocket, which is involved in substrate binding and
recognition, as well as in the interaction with the inhibitory
sequence of the R subunit1,17–18 (Fig. 1a). On the basis of the
known structure of the wild-type PKA holoenzyme19, we predict
that substitution of Leu206 by a bulky and positively charged
amino acid such as Arg could lead to direct steric hindrance
between the side chain of this amino acid and that of both Val115
and Tyr228 in the R subunit (Fig. 1c,d). For the second mutation,
which is more difﬁcult to evaluate since it involves the insertion
of an amino acid, it is noteworthy that Leu199 and Cys200 are
located next to Thr198 in the so-called activation loop. The latter
residue is phosphorylated after synthesis of the C subunit, which
is required for full catalytic activity. Furthermore, these residues
are located in a region of the C subunit that is oriented parallel to
the inhibitory sequence, where residues Gly201 as well as Leu199
are involved in main-chain hydrogen bonding interactions with
Val115 and Ala117 of the R subunit (Fig. 1b). Thus, the insertion
of an additional residue, especially one with a very bulky side
chain such as Trp, is also predicted to interfere with the
interaction between the C and the R subunits. On the basis of
these observations and the previous ﬁnding that both PKA Ca
mutants are constitutively active despite the presence of an excess
of R subunits and regardless of the intracellular concentration of
cAMP13, we hypothesized that both mutations might interfere
with the interaction between the C and R subunits, causing the C
subunits to be free and, thus, active even in the absence of cAMP.
Functional characterization of PKA Ca mutants in vitro.
As a ﬁrst step to verify our hypothesis, we performed
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Figure 1 | Location of Leu206Arg and Leu199_Cys200insTrp mutations.
(a–d) Zoomed in regions of the interface between the R (red) and C (green)
subunits based on the structure of the mouse full-length tetrameric
RIIb(2):Ca(2) holoenzyme19 (Protein Data Bank entry 3TNP). The inhibitory
sequence is indicated by an asterisk (*). (a) Position of Leu206, shown in
sticks. Val115 and Tyr228 in the R subunit are also depicted. (b) Position of
residues Leu199 and Cys200, both shown as sticks. Gly201 in the C subunit
as well as Val115 and Ala117 in the R subunit are also depicted. (c) Space-
ﬁlling representation of Leu206, Val115 and Tyr228. (d) In silico replacement
of Leu206 with Arg. The bulky and positively charged Arg side chain is
predicted to clash with Val115 and Tyr228 in the R subunit, all shown in
space-ﬁlling representation.
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co-immunoprecipitation (co-IP) experiments investigating the
basal association between PKA Ca mutants and R subunits. For
this purpose, we transfected HEK293 cells with FLAG-tagged
RIIb and either wild-type or mutant Ca subunits at comparable
expression levels. Using anti-FLAG antibodies, FLAG-tagged
RIIb was then immunoprecipitated from lysates of these cells and
analysed for association with endogenous or exogenous Ca sub-
units by western blot analyses using an antibody directed against
Ca. As expected, this resulted in a robust co-IP of the exogen-
ously expressed wild-type Ca subunit (Fig. 2). In contrast, only
faint signals were detected in case of the Ca mutants, suggesting a
much weaker interaction (Fig. 2). The immunoprecipitation was
speciﬁc as indicated by control experiments in which either the
FLAG-tagged RIIb subunit was omitted or the samples were
mock precipitated (Supplementary Fig. 1).
To further analyze the interaction between PKA Ca mutants
and R subunits, we devised a second approach that monitored the
basal association between the R and C subunits as well as their
dissociation during a stepwise increase of the cAMP concentra-
tion. For this purpose, we took advantage of the well-known
strong interaction of R subunits, but not of free C subunits, to
anion exchange matrices, such as DEAE-Sephacel20. We allowed
PKA from lysates of cells co-transfected with RIIb and either
wild-type or mutant Ca subunits to bind to DEAE-Sephacel.
Then, we loaded the samples into small chromatography
columns, eluted the columns with stepwise increasing
concentrations of cAMP and measured both the amount of
eluted Ca subunit (by western blot analysis) and PKA catalytic
activity (using a gel-based assay) in the collected fractions. When
lysates from cells co-transfected with wild-type Ca and RIIb
subunits were analysed, very little Ca subunit was found in the
ﬂow-through and initial washes (indicating strong binding), and
an elution peak of the Ca subunit was observed atB2 mM cAMP
(Fig. 3a), consistent with the afﬁnity of cAMP for the PKA
holoenzyme21. This corresponded well to a peak in PKA activity
(Fig. 3b). In contrast, when the wild-type Ca subunit was replaced
by either mutant, PKA activity and the Ca subunit were
recovered to a much larger extent already in the ﬂow-through
and/or wash fractions (Fig. 3a–c), suggesting that at most only a
weak interaction between the Ca mutants and wild-type R
subunits was present.
In addition, we used a well-established assay based on FRET
between cyan ﬂuorescent protein (CFP)-tagged R and yellow
ﬂuorescent protein (YFP)-tagged C subunits22,23 to monitor the
cAMP-induced dissociation of the PKA holoenzyme (Fig. 4a).
This assay was performed on cell lysates of Cos-7 cells that
had been co-transfected with wild-type or mutant Ca and
either a type-I (RIa) or a type-II (RIIb) regulatory subunit.
Addition of cAMP to lysates containing wild-type CFP-RIIb and
YFP-Ca subunits caused a rapid decrease in FRET, indicating
that the C and R subunits were dissociating (Fig. 4b,d).
In contrast, no change in FRET was observed when the
same experiment was performed with either Ca mutant
(Fig. 4c,d). Similar results were obtained when RIa was used
instead of RIIb (Fig. 4e).
To assess potential effects of the Ca mutations on PKA
catalytic activity, we compared the PKA activity of cell lysates
containing either wild-type or mutant Ca subunits in the
presence of a saturating concentration of cAMP. For this
purpose, we overexpressed tagged Ca and RIIb subunits and
correlated the cAMP-stimulated PKA activity in the cell lysates
with the expression levels of the exogenous Ca subunits, using
four different amounts of samples (Fig. 5). No statistically
signiﬁcant differences were observed among the two mutants and
the wild-type Ca subunit. These data indicate that the maximal
activity (that is, the one measured in the presence of saturating
cAMP concentrations) of both Ca mutants did not differ from
that of the wild-type Ca subunit.
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Figure 2 | Effect of Leu206Arg and Leu199_Cys200insTrp mutations on
the association with R subunits analysed by co-IP. Cells were transfected
with FLAG-tagged RIIb (RIIb-FLAG) and either wild-type (WT) or mutant Ca
subunits. Shown are representative western blot analyses of Ca and RIIb after
FLAG-tagged RIIb was immunoprecipitated with a FLAG-speciﬁc antibody (IP:
FLAG). The western blot analyses in the lower part of the ﬁgure (input) control
for expression levels of wild-type or mutant Ca and RIIb. These analyses were
repeated in at least six independent experiments with similar results.
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Figure 3 | Effect of Leu206Arg and Leu199_Cys200insTrp mutations on the retention of Ca subunits on DEAE-Sephacel. (a–c) Results of experiments
where the lysates of cells co-transfected with R and C subunits were pre-bound to DEAE-Sephacel columns, which have a high afﬁnity for R subunits, and
eluted with wash buffer followed by the same buffer containing increasing concentrations of cAMP. Data are from 4 independent experiments per
condition. (a) Western blot analysis for Ca. Shown are three representative blots. (b) PKA activity (mean±s.e.m.) measured in the different fractions
(n¼4). (c) Comparison of the fraction of PKA activity (mean±s.e.m.) collected during the ﬁrst two washes with buffer (n¼4). *Po0.05 versus WT by
one-way ANOVA followed by Bonferroni’s post-hoc test.
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Functional assessment of PKA Ca mutants in living cells. Our
in vitro results provided strong evidence that both mutations in
the Ca subunit interfered with the formation of a stable PKA
holoenzyme. To prove that the same was occurring also in intact
cells, we performed a series of live-cell experiments in which we
monitored the association between ﬂuorescently tagged PKA
subunits by means of FRET microscopy. To begin with, we
assessed the basal interaction between PKA Ca mutants and R
subunits by acceptor photobleaching. Whereas this method was
able to detect an interaction between wild-type Ca and RIIb
subunits, no statistically signiﬁcant interactions were measured
in case of both Ca mutants (Fig. 6a). Then, we monitored in
real-time FRET between PKA Ca mutants and R subunits in
cells that were stimulated with a pharmacological activator of
adenylyl cyclase (forskolin) to increase intracellular cAMP
concentrations. Whereas a large decrease in FRET, indicative of
PKA dissociation, was detected in the presence of wild-type Ca,
virtually no changes were observed in the case of either Ca
mutant (Fig. 6b).
Taken together, these data indicate that both PKA Ca mutants
identiﬁed in cortisol-secreting adrenal adenomas have normal
enzymatic activity, but are unable to form a stable complex with R
subunits both in vitro and in living cells, thus providing an
explanation for their high constitutive activity and the loss of
regulation by cAMP.
Discussion
This study provides a molecular basis to explain the pathogenic
role of PRKACAmutations, which we have previously found to be
frequently present in cortisol-secreting adrenal adenomas13. Our
ﬁndings indicate that both mutations found in our previous study
(Leu206Arg and Leu199_Cys200insTrp) interfere with the
formation of a stable PKA holoenzyme, thus rendering the
mutant PKA Ca subunits constitutively active.
Very recent whole-exome-sequencing studies have conﬁrmed
the high frequency of the PRKACA variant Leu206Arg in
cortisol-secreting adrenal adenomas14–16. These studies found
an increased phosphorylation of PKA substrates in the presence
of the Leu206Arg variant, in agreement with our previous
ﬁndings13. However, the mechanism of action of the Leu206Arg
mutation is highly controversial. On the basis of the ﬁnding that
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Figure 4 | Effect of Leu206Arg and Leu199_Cys200insTrp mutations on cAMP-dependent PKA dissociation. (a) Schematic representation of the
ﬂuorescently labelled PKA holoenzyme. In the absence of cAMP, FREToccurs between CFP attached to the R subunits and YFP attached to the C subunits,
resulting in high YFP and low CFP emission. On cAMP binding to the R subunits and dissociation of the C subunits, FRETdrops, leading to high CFP and low
YFP emission. (b,c) Representative FRET traces obtained in lysates from cells transfected with RIIb together with either wild-type Ca (b) or the Leu206Arg
mutant (c). cAMP addition causes a robust drop of FRET in the presence of wild-type Ca (b) but not in the presence of the Leu206Arg mutant (c). The
black traces were obtained by smoothing the data using a moving average of 13 neighbouring data points. (d,e) Comparison of the changes in FRET ratio
(mean±s.e.m.) caused by cAMP addition among wild-type (WT) and mutant Ca co-expressed with either RIIb (d) or RIa (e) subunits (n¼4 for WT Ca
and Leu199_Cys200insTrp mutant, n¼ 5 for Leu206Arg mutant). Data are from at least four independent experiments per condition. *Po0.05 versus WT,
**Po0.01 versus WT, ***Po0.001 versus WT by one-way ANOVA followed by Bonferroni’s post-hoc test.
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Figure 5 | Effect of Leu206Arg and Leu199_Cys200insTrp mutations on
catalytic activity. Cells were transfected with wild-type or mutant Ca
subunits tagged with YFP together with the CFP-tagged RIIb subunit. Four
different amounts of cells lysates were used. The PKA catalytic activity was
measured in the presence of a saturating concentration of cAMP (200 mM).
The amount of exogenous Ca subunits was quantiﬁed using an antibody
that recognizes YFP. Shown are the results (mean±s.e.m.) of three
independent measurements. Data were ﬁt by linear regression. Differences
among slopes are not statistically signiﬁcant by an F-test.
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the Leu206Arg variant co-immunoprecipitated with R subunits,
as well as of a higher basal PKA activity in cells co-transfected
with the Leu206Arg variant and R subunits compared with cells
co-transfected with wild-type Ca and R subunits, Cao et al.14
concluded that the interaction of the Leu206Arg variant with R
subunits is preserved. To explain their ﬁndings, they hypothesized
that the Leu206Arg mutation might increase PKA activity by
enhancing substrate interaction and/or the catalytic activity of the
enzyme14. In contrast, two other studies15,16 did not detect any
co-IP between the Leu206Arg variant and RIa.
Our study provides a direct measurement of the association of
Leu206Arg and Leu199_Cys200insTrp mutants with R subunits
under basal conditions and after cAMP stimulation both in vitro
and in intact cells. Our results clearly indicate the presence of a
major defect in this association for both Ca mutants, which is
already observable in the absence of cAMP. These ﬁndings are
consistent with the virtual lack of regulation by an excess of R
subunits or by cAMP13. Whereas we cannot exclude that either
mutation might also have an impact on substrate speciﬁcity, we
did not observe a difference in the PKA activity (measured with
Kemptide as a substrate) of samples containing either wild-type
or mutant Ca in the presence of a saturating concentration of
cAMP. Taken together, these data provide a molecular
explanation for the increased PKA activity in cells harbouring
either mutation identiﬁed in our previous study.
The zona fasciculata of the adrenal cortex, which is responsible
for glucocorticoid production, is under the strict control of the
adrenocorticotropic hormone (ACTH)24. ACTH activates a
G-protein-coupled receptor located on the surface of
adrenocortical cells, which induces both cortisol production and
cell proliferation through activation of the cAMP/PKA
pathway25–27. Thus, a constitutive activation of PKA, as seen in
the presence of PRKACA-activating mutations, is expected to lead
to deregulated cortisol production and increased cell replication,
similarly to what is seen with PRKAR1A-inactivating and GNAS-
activating mutations5–8.
PRKACA-activating mutations appear to be responsible for
Cushing’s syndrome, which, if not promptly recognized and
effectively treated, is associated with high morbidity and
mortality28. A better understanding of the molecular mecha-
nisms at the basis of adrenal Cushing’s syndrome might thus
allow improving its diagnosis and provide novel and more
rational pharmacological therapies. In addition, given the
essential role of PKA signalling in virtually all cells of our
organism, similar pathological mechanisms might be implicated
in other diseases of both endocrine and non-endocrine origin.
Thus, our ﬁndings provide novel and essential information to
understand the pathogenesis of cortisol-secreting adrenal
tumours and possibly other PKA-pathies, which could have
important clinical and pharmacological implications.
In summary, our study indicates that both PRKACA
mutations found in cortisol-secreting adrenal tumours affect a
key region of the Ca subunit that is involved in interaction with
the inhibitory sequence of the R subunits. Both mutations
interfere with this interaction, and thus with the formation of a
stable PKA holoenzyme. The resulting free mutant Ca subunits
are active irrespective of the intracellular concentration of
cAMP, which leads to constitutive PKA activation and
phosphorylation of PKA targets. Nevertheless, the maximal
catalytic activity of both Ca mutants is not altered. These
ﬁndings provide a biochemical explanation for the increased
PKA activity observed in adrenal tumours harbouring these
PRKACA mutations and also a causal mechanism for the
associated Cushing’s syndrome.
Methods
Plasmids. Plasmids encoding wild-type human RIa, RIIb and Ca subunits were
purchased from Origene. Mutations in the sequence coding for the Ca subunit
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Figure 6 | FRETmeasurements in living cells. Cells were transfected with wild-type or mutant Ca subunits tagged with YFP together with the CFP-tagged
RIIb subunit. (a) Basal association of Leu206Arg and Leu199_Cys200insTrp mutants with RIIb in living cells as measured by acceptor photobleaching
FRET. Data (mean±s.e.m.) are taken from more than 90 cells analysed in six independent experiments for each condition. *Po0.05, **Po0.001; NS,
statistically not signiﬁcant by one-way ANOVA followed by Bonferroni’s post-hoc test. (b) Effect of increasing intracellular cAMP concentrations with
forskolin (fsk, 10mM) on the association between CFP-tagged RIIb and either wild-type or mutant Ca subunits tagged with YFP. Data (mean±s.e.m.) are
taken from 9 to 16 cells per condition measured in three independent experiments.
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were introduced by PCR as described13. The constructs were then subcloned into
the pcDNA3 vector by standard procedures. Speciﬁcally, fragments containing the
entire PKA subunit coding sequences were ampliﬁed by PCR using primers
containing a KpnI site (RIIb subunit) or HindIII (C and RIa subunits) at the 50-end
and a NotI site at the 30-end and inserted between the KpnI (RIIb subunit) or
HindIII (C and RIa subunits) and NotI sites of pcDNA3. Plasmids encoding YFP-
tagged human PKA Ca and CFP-tagged human RIIb subunits were generated by
replacing mouse subunits with human PKA subunits in the constructs originally
described by Zaccolo et al.23 Speciﬁcally, fragments containing the entire PKA
subunit coding sequences without stop codon were ampliﬁed by PCR using
primers containing a NotI site at the 50-end and a ClaI site at the 30-end and used
to replace the mouse subunits contained between a NotI site and a ClaI site in the
original vectors. Mutations were introduced by PCR following standard methods.
For generating the plasmid encoding the FLAG-tagged RIIb subunit, a fragment
containing the entire coding sequence of the human RIIb subunit was ampliﬁed by
PCR with a forward primer containing the FLAG tag (amino-acid sequence
DYKDDDDA) and a KpnI site at the 50-end and a reverse primer containing a
NotI site at the 30-end. This fragment was subsequently inserted between the KpnI
and NotI sites of pcDNA3.
Cell culture and transfection. HEK293 and Cos-7 cells were obtained from
American Type Culture Collection. Cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% FCS, 0.1mgml 1 streptomycin and
100Uml 1 penicillin at 37 C and 5% (vol/vol) CO2. Cell culture reagents were
from PAN-Biotech. Cos-7 cells were seeded at a density of 2.5 106 cells per well
onto 15-cm Petri dishes and allowed to grow for 6 h, after which they were trans-
fected with Fugene HD (Promega) according to the manufacturer’s protocol.
HEK293 cells were seeded at a density of 1.2 106 cells per well onto 10-cm Petri
dishes or 0.25 106 cells per well onto six-well plates containing 24-mm round glass
coverslips and allowed to grow for 24 h, after which they were transfected with the
Effectene transfection kit (Qiagen) according to the manufacturer’s protocol. Ratios
of transfected R and C subunit DNA were optimized to favour association between
C and R subunits13. All experiments were performed 48h after transfection.
Preparation of membrane-free cell lysates. Cells were washed thrice with ice-
cold phosphate-buffered saline, scraped from the plate and resuspended in 600 ml
5/2 buffer (5mM Tris-HCl, 2mM EDTA, pH 7.4). Thereafter, samples were
homogenized using an Ultraturrax device for 20 s on ice and centrifuged at
100,000 g for 30min at 4 C to remove membranes.
FRETmeasurements on cell lysates. FRET measurements on membrane-free cell
lysates were performed using a Perkin-Elmer LS50B ﬂuorescence spectrometer.
The excitation was set at 437±10 nm to excite CFP and at 490±10 nm to excite
YFP. Dissociation of the PKA holoenzyme during addition of cAMP (ﬁnal
concentration¼ 200mM) was followed in real-time by monitoring CFP emission at
475±10 nm and YFP emission at 525±10 nm on CFP excitation at 437±10 nm.
Separation of R and C subunits on DEAE-Sephacel columns. Membrane-free
cell lysates obtained from three 15-cm Petri dishes were mixed with 300ml of a 1:1
DEAE-Sephacel slurry (GE Healthcare Life Sciences) in 5/2 buffer and incubated for
2 h at 4 C under continuous rotation. Then, the samples containing DEAE-Sephacel
were packed into mini spin columns. After centrifugation at 7,600 g for 1min to
remove the ﬂow-through and three washes with 5/2 buffer, the columns were
repeatedly eluted with increasing concentrations of cAMP, ranging from 20nM to
2mM. Each elution step was repeated twice. All procedures were performed at 4 C.
PKA activity assay. PKA catalytic activity was measured using the PepTag non-
radioactive cAMP-dependent protein kinase assay (Promega), which uses a
ﬂuorescent Kemptide peptide as substrate, following the manufacturer’s instruc-
tions. Images of the gels were acquired with a gel documentation system (Herolab)
and analysed using the ImageJ software (http://rsbweb.nih.gov/ij).
Co-immunoprecipitation. Cells were lysed with a buffer containing 150mM NaCl,
1mM EDTA, 1mM EGTA, 1% Triton X-100 and 20mM Tris-HCl, pH 7.5, sup-
plemented with protease inhibitors (Complete Mini, Roche). Lysates were cen-
trifuged at 20,000 g for 10min at 4 C. Supernatants were transferred to a new vial
and incubated with protein-A Sepharose for 2 h at 4 C under continuous rotation.
Protein-A Sepharose was either preincubated with a rabbit polyclonal anti-FLAG
antibody (Sigma-Aldrich, # F7425) or without antibodies to control for unspeciﬁc
binding of Ca to protein-A Sepharose (mock precipitation). Preincubations were
performed overnight at 4 C under continuous rotation. After the incubation of
protein-A Sepharose with the cell lysates, samples were washed ﬁve times with lysis
buffer. Proteins were removed from protein-A Sepharose by addition of Laemmli
buffer, followed by incubation for 3min at 95 C.
Western blot analysis. Unless otherwise indicated, samples were mixed with
Laemmli buffer and incubated for 2min at 95 C. Proteins were separated by
electrophoresis on a 10% SDS polyacrylamide gel and electrotransferred to a
polyvinylidene diﬂuoride membrane (Merck Millipore). Membranes were blocked
with TBS-T (Tris-buffered saline with Tween 20) bufferþ 5% milk for 2 h at room
temperature and incubated overnight at 4 C with the indicated primary antibody,
followed by incubation with an appropriate horseradish peroxidase-conjugated
secondary antibody for 1 h at room temperature. PKA Ca subunits were detected
with a rabbit polyclonal antibody (Cell Signaling # 4782, 1:5,000 dilution) or with a
mouse monoclonal antibody (BD Transduction Laboratories # 610980, 1:4,000
dilution). YFP-tagged Ca subunits were detected using a rabbit polyclonal antibody
against green ﬂuorescent protein (Invitrogen # A6455, 1:1,000 dilution). FLAG-
tagged RIIb subunits were detected using a mouse monoclonal anti-FLAG antibody
(Sigma-Aldrich # F3165, 1:8,000 dilution). Uncropped scans of western blots are
given in Supplementary Fig. 2.
FRET measurements in living cells. Imaging was performed in a buffer con-
taining 144mM NaCl, 5.4mM KCl, 2mM CaCl2, 1mM MgCl2 and 10mM HEPES,
pH 7.3.
Ratiometric FRET experiments were performed on a Zeiss Axiovert 200
inverted microscope equipped with a 63 oil-immersion objective, a polychrome
V light source (Till Photonics), a 505 DCXR beam splitter and a CoolSNAP HQ
CCD Camera (Photometrics). Images were acquired every 5 s with 5-ms
illumination time and monitored with the MetaFluor 5.0 software (Molecular
Devices) as the ratio between emission at 535±20 nm (YFP) and emission at
480±15 nm (CFP), on excitation at 436±10 nm. The YFP emission was corrected
for direct excitation of YFP at 436 nm and the bleedthrough of CFP emission into
the YFP channel.
Acceptor photobleaching experiments were performed on a TCS SP5 confocal
microscope (Leica Microsystems) using a  63 oil-immersion objective. CFP was
excited using the 458-nm line of a 65-mW argon-ion laser. CFP emission was
detected with a GaAsP hybrid detector in a range from 465 to 490 nm. YFP
bleaching was performed using the 514-nm line of the same laser set at 50%. To
measure acceptor photobleaching, two separate CFP images were acquired, one
before and one after YFP photobleaching. Images were analysed using the ImageJ
software. After subtracting the background, FRET efﬁciency (E) was calculated
from these images using the following equation29:
E ¼ 1 I0
Ibl
ð1Þ
where I0 is the CFP intensity before and Ibl is the corresponding value after
photobleaching.
Structural analysis of human mutations. Structural images were prepared using
the PyMOL software (www.pymol.org). The structure of the mouse full-length
tetrameric RIIb(2):Ca(2) holoenzyme19 (Protein Data Bank entry 3TNP) was used
to display the PKA catalytic (Ca) and regulatory (RIIb) subunit structures.
Statistical analyses. Statistical analyses were performed using Prism 4.0
(GraphPad). Values are given as mean±s.e.m. Differences between three or more
groups were assessed by one-way ANOVA followed by Bonferroni’s post-hoc test.
Differences were considered signiﬁcant for values of Po0.05.
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